Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM
Status:
Recruiting
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
As optimal tolerance is the key for developing new treatments for the very elderly
population, the aim of the study is to compare the efficacy and tolerance of isatuximab in
combination with lenalidomide+dexamethasone (Rd) versus Rd only in very elderly patients aged
70 years or older. ln sum, a clear and clinically highly relevant benefit is expected with
the isatuximab-based triple combination compared to the standard Rd doublet.
Phase:
Phase 2
Details
Lead Sponsor:
Arbeitsgemeinschaft medikamentoese Tumortherapie
Collaborators:
Assign Data Management and Biostatistics GmbH Medical University of Vienna Sanofi University of Navarra WiSP GmbH